Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
School-leaver to retiree: ASX stocks I'd buy for each age bracket
I'd invest $10,000 into these excellent ASX shares for the long-term
I'd start snapping up quality cheap ASX shares before stock prices start rising!
Why is the Volpara share price rocketing 13% today?
ASX wealth: How I'd aim to turn $50,000 into $500,000 for retirement
2 ASX growth shares I'd buy over Nvidia
2 ASX growth shares I rate as buys for their big potential
3 ASX growth shares I'd buy with $1,500 right now
Small Cap Shares
Why I'd buy small-cap shares over ASX blue chips at every chance
How to invest
How I'd build a 'best ASX stocks to buy right now' list
Share Market News
3 ASX shares using AI to help supercharge profits
How I'm aiming to find under-the-radar cheap ASX shares right now
No, the ASX healthcare share has not yet paid any dividends.
Volpara listed on 27 April 2016.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Volpara Health Technologies Ltd (ASX: VHT) is a small but growing research, development, and manufacturing company that provides breast screening technology and risk analysis for patients and medical professionals.
Volpara’s artificial intelligence-powered software for early detection of breast cancer is used by more than 2,000 facilities and more than 5,600 mammography technologists, impacting nearly 15 million patients globally. Volpara is based in Wellington, New Zealand, and also has a US office in Seattle.
|27 Nov 2023||$0.80||$0.05||6.67%||449,665||$0.72||$0.80||$0.71|
|24 Nov 2023||$0.75||$0.02||2.74%||129,691||$0.73||$0.75||$0.72|
|23 Nov 2023||$0.73||$0.01||1.39%||50,407||$0.73||$0.73||$0.71|
|22 Nov 2023||$0.72||$0.01||1.40%||271,044||$0.72||$0.75||$0.71|
|21 Nov 2023||$0.72||$0.02||2.86%||172,092||$0.70||$0.72||$0.69|
|20 Nov 2023||$0.70||$-0.02||-2.78%||80,274||$0.74||$0.74||$0.70|
|17 Nov 2023||$0.72||$-0.02||-2.70%||16,532||$0.73||$0.74||$0.72|
|16 Nov 2023||$0.74||$0.03||4.23%||177,958||$0.72||$0.75||$0.71|
|15 Nov 2023||$0.71||$0.03||4.44%||109,596||$0.68||$0.71||$0.68|
|14 Nov 2023||$0.68||$-0.01||-1.46%||193,179||$0.69||$0.69||$0.67|
|13 Nov 2023||$0.69||$0.00||0.00%||75,725||$0.70||$0.70||$0.68|
|10 Nov 2023||$0.69||$0.01||1.48%||47,139||$0.70||$0.70||$0.68|
|09 Nov 2023||$0.68||$-0.03||-4.23%||126,674||$0.71||$0.72||$0.67|
|08 Nov 2023||$0.71||$-0.02||-2.76%||42,837||$0.73||$0.73||$0.71|
|07 Nov 2023||$0.73||$0.01||1.40%||153,759||$0.71||$0.73||$0.68|
|06 Nov 2023||$0.72||$-0.01||-1.39%||75,797||$0.72||$0.74||$0.70|
|03 Nov 2023||$0.72||$-0.02||-2.72%||68,614||$0.74||$0.74||$0.72|
|02 Nov 2023||$0.74||$-0.01||-1.34%||42,872||$0.74||$0.74||$0.72|
|01 Nov 2023||$0.75||$0.01||1.36%||208,106||$0.72||$0.76||$0.71|
|31 Oct 2023||$0.74||$0.04||5.76%||153,613||$0.70||$0.74||$0.70|
|17 Aug 2023||Mark Bouw||Issued||450,000||$585,000||
Issue of options.
|02 Jun 2023||Teri Thomas||Sell||3,577||$2,546||
|01 Jun 2023||Teri Thomas||Buy||75,280||$57,213||
Conversion of securities. As per announcement on 02-06-2023
|01 Jun 2023||Teri Thomas||Exercise||75,280||$57,213||
Conversion of securities. 150,561 RSUs, As per announcement on 02-06-2023
|16 Feb 2023||Roger Allen||Exercise||300,000||$150,000||
Exercise of options.
|Mr Roger Allen||Non-Executive Director||Jun 2010||
Roger was Volpara s first major investor, joined the Board
prior to FDA approval in June 2010, and was Chair from
October 2015 to March 2019.
Roger is a well-known entrepreneur, venture capitalist (VC),
and social impact investor and philanthropist whose global
career has spanned over 50 years. He helped pioneer the
Australian technology industry through the Computer
Power Group, one of the first Australian-founded tech
companies to scale globally and subsequently IPO in 1987,
turning over approx. $1B in today s currency. Following
the companys acquisition in 1995, he cofounded Allen &
Buckeridge Pty Ltd, one of the first early-stage VC firms.
|Mr John Dimitrious Pavlidis||Non-Executive Director||Feb 2015||
John Pavlidis joined the VHT board in February
2015 and has more than 30 years of experience
as a senior healthcare executive, CEO, or
company director in the areas of womens health,
diagnostic imaging, image analysis and artificial
intelligence, and cardiovascular therapies.
|Mr Paul Reid||Non-Executive DirectorNon-Executive Chairman||Mar 2018||
Paul joined the Board in March 2018 and brings extensive
commercial experience gained across a range of
technology/Software as a Service businesses.
He was the founding CEO and Chairman of Figured
Limited, a fintech SaaS company that provides
management accounting software to farmers in the
United States, the United Kingdom ,
Australia, and New Zealand . Figured was the
NZ Hi-Tech Startup Company of the Year in 2016 and
has grown at an incredible pace, funded by private,
corporate and venture capital (VC) investors.
|Ms Karin Lindgren||Non-Executive Director||Jan 2020||
Karin joined the Board in 2020. She brings over 35 years
experience in health information technology as a senior
technology executive and law firm partner. As one of
the earliest healthcare technology lawyers in the USA,
Karin has an in-depth knowledge of data governance,
data privacy, SaaS, and US healthcare, and has extensive
professional networks across the IT landscape
|Ms Ann Custin||Non-Executive Director||Sep 2021||
network of industry contacts from an extensive
career in healthcare across Europe, the Americas,
and Asia. Her most recent executive role was with
Siemens Healthineers, where she served as both CFO
and board director of Siemens Medical Solutions.
Prior to this role, Ann served as Chief Operating
and Financial Officer of Scientx and President &
CEO of USA Draeger Medical Systems, Inc.
|Ms Teri Thomas||Chief Executive OfficerManaging Director||Apr 2022||
Teri joined the Board in October 2022. She has a
long history of executive management in healthcare
IT ranging from strategy and operations to running
global sales and marketing teams. This includes a
20-year career at Epic, a global leader in electronic
health record (EHR) systems and other software
solutions used by hospitals and healthcare
organisations in the United States and internationally
|Mr Mark Bouw||Non-Executive Director||Jan 2023||
Mr Bouw is a experienced senior healthcare CEO .He is a visiting consultant at Stanford University Graduate Business School Seed Program in the United States and is a visiting mentor for Stanfords Ignite program.
|Mr Craig Hadfield||Chief Financial OfficerJoint Company Secretary||Mar 2017||
|Mr Fred Struve||General CounselJoint Company Secretary||Oct 2022||
|Craig Hadfield||Chief Financial OfficerJoint Company Secretary||
|Fred Struve||General CounselJoint Company Secretary||
|No Top 20||27,534,688||10.84%|
|Patagorang Pty Ltd||18,467,848||7.27%|
|Ralph Highnam And Kyc Trustees 106 Limited <Highnam Share A/C>||16,213,561||6.38%|
|Citicorp Nominees Pty Limited||11,830,450||4.66%|
|HSBC Custody Nominees (Australia) Limited||8,187,911||3.22%|
|Custodial Services Limited <Beneficiaries Holding A/C>||8,154,911||3.21%|
|Bnp Paribas Noms (Nz) Ltd <Drp>||7,061,556||2.78%|
|Prof Sir Michael Brady||6,619,075||2.61%|
|Mr Marcus Sarner||5,980,404||2.35%|
|National Nominees Limited||4,728,818||1.86%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient||4,420,193||1.74%|
|Sir Martin Francis Wood||3,004,655||1.18%|
|Lady Kathleen Audrey Wood||3,004,654||1.18%|
|BNP Paribas Noms Pty Ltd <Drp>||2,527,511||0.99%|
|Prof Martin Yaffe||1,966,483||0.77%|
|Mr John Anthony Dell||1,928,864||0.76%|
|BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Limited||1,917,409||0.75%|
|Prof Nico Karssemeijer||1,806,806||0.71%|
|Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C>||1,519,964||0.60%|
|RX HOUSE TRUST PTY LTD||880,758||0.35%|